CompletedPhase 2NCT02111161
Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
Studying Necrotizing soft tissue infection
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Anders Perner
- Principal Investigator
- Anders Perner, ProfessorRigshospitalet, Denmark
- Intervention
- IVIG (Privigen)(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2016
Study locations (1)
- Dept. of Intensive Care 4131, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Danmark, Denmark
Collaborators
CSL Behring
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02111161 on ClinicalTrials.govOther trials for Necrotizing soft tissue infection
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07107555Necrotizing Soft Tissue InfectionsEuropean Society for Trauma and Emergency Surgery
- RECRUITINGNANCT07120386Irrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue InfectionsHealthPartners Institute
- RECRUITINGNANCT06857708The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®Benjamin T. Miller
- RECRUITINGNANCT03482245The Role of Circadian Clock Proteins in Innate and Adaptive ImmunityWashington University School of Medicine
- RECRUITINGNCT06002607Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue InfectionsUniversity of California, Irvine
- RECRUITINGNCT07359651FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI).University of Cagliari